BioCentury | May 25, 2018
Clinical News

FDA approves BioMarin's phenylketonuria drug

...6R-BH4). Sales of that drug were $407.5 million in 2017. BioMarin expects generic competition for Kuvan...
BioCentury | May 24, 2018
Company News

FDA approves BioMarin's phenylketonuria drug

...6R-BH4). Sales of that drug were $407.5 million in 2017. BioMarin expects generic competition for Kuvan...
...$4.20 to $92.48 in after-hours trading after the approval was announced. Paul Bonanos Kuvan (6R-BH4, biopten, sapropterin dihydrochloride, Phenoptin) Pegvaliase...
BioCentury | May 4, 2017
Company News

BioMarin tops 1Q17 estimates

...narrower-than-expected loss, driven by growth in sales of rare disease treatments Vimizim elosulfase alfa and Kuvan...
...$106 million, up 45% year-over-year and ahead of a $96.6 million consensus, while revenue from Kuvan...
...Ajer said new patient starts and the addition of a new market drove the gains. Kuvan...
BioCentury | Apr 21, 2017
Company News

BioMarin, Par settlement deal

...BioMarin granted Endo's Par Pharmaceutical company non-exclusive U.S. rights to market Kuvan sapropterin as a generic...
...resolves U.S. patent litigation between the parties. Kuvan is a small molecule formulation of tetrahydrobiopterin (6R-BH4...
BioCentury | Mar 22, 2016
Top Story

Mixed Phase III PKU results for BioMarin's pegvaliase

...R&D Henry Fuchs noted on the call that FDA approved BioMarin's marketed PKU drug, Kuvan sapropterin dihydrochloride...
...the Society of Inherited Metabolic Disorders meeting. In October, BioMarin regained rights to pegvaliase and Kuvan...
BioCentury | Mar 14, 2016
Analyst Picks & Changes

Analyst picks & changes

...by Vimizim elosulfase alfa for mucopolysaccharidosis IVA and the addition of ex-U.S. sales of Kuvan sapropterin dihydrochloride...
...meet the primary endpoint in a Phase III trial in PKU in March. BioMarin reacquired Kuvan...
BioCentury | Jan 11, 2016
Finance

Sowing season

...treat phenylketonuria (PKU). In October, BioMarin regained rights to pegvaliase and marketed PKU drug Kuvan sapropterin dihydrochloride...
BioCentury | Dec 21, 2015
Finance

Blood money

...debilitating consequences, such as developmental deficits in children. The lone drug for the condition, Kuvan sapropterin dihydrochloride...
BioCentury | Oct 26, 2015
Emerging Company Profile

Building bacteria

...program focuses on PKU, which also requires a low-protein diet even for patients on Kuvan sapropterin dihydrochloride...
BioCentury | Oct 5, 2015
Company News

BioMarin, Serono deal

...BioMarin will regain rights to phenylketonuria (PKU) treatments Kuvan sapropterin dihydrochloride and pegvaliase ( BMN 165...
...Merck’s annual sales of Kuvan. BioMarin said it expects $320-$350 million in total revenue from Kuvan...
...Tokyo:4568, Tokyo, Japan) retains Japanese rights to Kuvan, a small molecule formulation of tetrahydrobiopterin ( 6R-BH4...
Items per page:
1 - 10 of 159